clinical trial · NCT07239336
Study of DONQ52 in Active Celiac Disease
Celiac DiseasePlacebo DONQ52Simulated Inadvertent Gluten Exposure (SIGE) capsuleDONQ52Simulated Inadvertent Gluten Exposure (SIGE) capsule
brief summary
The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
started
Dec 16, 2025
primary completion
Jun 15, 2027
completion
Dec 15, 2027
last updated
Apr 20, 2026
official title
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate The Efficacy and Safety of DONQ52 in Active Celiac Disease Patients Who Have Duodenal Mucosal Damage and Persistent Symptoms Despite Attempting A Gluten-free Diet (DAISY STUDY)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol